MedTrace Logo

Safety Study of High Doses of Zinc in ALS Patients

NCT01259050 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-03-12

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.

Conditions

Interventions

DRUG

Zinc and Copper

Optizinc 90 mg/d Copper 1 mg

Sponsors & Collaborators

  • Phoenix Neurological Associates, LTD

    lead OTHER

Principal Investigators

  • Todd D Levine, MD · Phoenix Neurological Associates, LTD

  • David S Saperstein, MD · Phoenix Neurological Associates, LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-01-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01259050 on ClinicalTrials.gov